Brand-name drug companies could put off introducing new medicine in Canada and scale back research here if the country makes a major shift to cheaper generic alternatives under a national pharmacare plan, according to an internal federal analysis.
After years of lobbying the province, the Ontario Pharmacists Association (OPA) is finally getting new prescriptive authorities for the assessment and treatment of known common illnesses.
